Literature DB >> 10362893

Apolipoprotein E phenotypes in demented and cognitively impaired patients with and without cerebrovascular disease.

L Traykov1, A S Rigaud, L Caputo, R Couderc, J Coste, J L Michot, J de Rotrou, P Amouyel, F Forette, F Boller.   

Abstract

Controversy exists regarding the apolipoprotein E (ApoE) epsilon4 allele association with vascular dementia (VaD), ranging from increased epsilon4 frequency, similar to that found for Alzheimer's disease (AD), to no association between the epsilon4 allele and VaD. To clarify further the relationship between ApoE alleles polymorphism and cerebrovascular disease (CVD) in demented and cognitively impaired patients, we examined the ApoE phenotypes in a sample of 280 patients: 155 with AD, 21 with VaD, 32 with mixed dementia (MD), 45 with mild cognitive impairment (MCI) but without CVD, and 27 in which vascular disease was the most probable cause of cognitive decline [vascular mild cognitive impairment (VMCI)]. Our results show that the frequency of the ApoE epsilon4 allele in patients over 70 years old with clinically diagnosed VaD and VMCI does not differ significantly from that of controls. In contrast, ApoE epsilon4 allele-bearing individuals had greater risk of having late-onset AD (OR = 8.8; 95% CI 3.7-21.0), or non-vascular cognitive impairment (OR = 7.0; 95% CI 2.5-19.0). Copyright 1999 Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10362893     DOI: 10.1046/j.1468-1331.1999.640415.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  7 in total

Review 1.  Is apolipoprotein E4 an important risk factor for vascular dementia?

Authors:  Troy T Rohn
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

2.  Cognitive impact of subcortical vascular and Alzheimer's disease pathology.

Authors:  Helena C Chui; Chris Zarow; Wendy J Mack; William G Ellis; Ling Zheng; William J Jagust; Dan Mungas; Bruce R Reed; Joel H Kramer; Charles C Decarli; Michael W Weiner; Harry V Vinters
Journal:  Ann Neurol       Date:  2006-12       Impact factor: 10.422

Review 3.  Vascular cognitive disorder. A biological and clinical overview.

Authors:  Leontino Battistin; Annachiara Cagnin
Journal:  Neurochem Res       Date:  2010-12-03       Impact factor: 3.996

Review 4.  Poststroke dementia in the elderly.

Authors:  Marie-Anne Mackowiak-Cordoliani; Stéphanie Bombois; Armelle Memin; Hilde Hénon; Florence Pasquier
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 5.  Cognition, language, and clinical pathological features of non-Alzheimer's dementias: an overview.

Authors:  Jamie Reilly; Amy D Rodriguez; Martine Lamy; Jean Neils-Strunjas
Journal:  J Commun Disord       Date:  2010-05-06       Impact factor: 2.288

6.  Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program.

Authors:  Thomas G Beach; Charles H Adler; Lucia I Sue; Geidy Serrano; Holly A Shill; Douglas G Walker; LihFen Lue; Alex E Roher; Brittany N Dugger; Chera Maarouf; Alex C Birdsill; Anthony Intorcia; Megan Saxon-Labelle; Joel Pullen; Alexander Scroggins; Jessica Filon; Sarah Scott; Brittany Hoffman; Angelica Garcia; John N Caviness; Joseph G Hentz; Erika Driver-Dunckley; Sandra A Jacobson; Kathryn J Davis; Christine M Belden; Kathy E Long; Michael Malek-Ahmadi; Jessica J Powell; Lisa D Gale; Lisa R Nicholson; Richard J Caselli; Bryan K Woodruff; Steven Z Rapscak; Geoffrey L Ahern; Jiong Shi; Anna D Burke; Eric M Reiman; Marwan N Sabbagh
Journal:  Neuropathology       Date:  2015-01-26       Impact factor: 1.906

7.  Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging.

Authors:  Ging-Yuek R Hsiung; A Dessa Sadovnick; Howard Feldman
Journal:  CMAJ       Date:  2004-10-12       Impact factor: 8.262

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.